MSc (Biochemistry) / Department of Biochemistry / Malaria is caused by protozoa of the genus Plasmodium. Malaria accounts for approximately more than half a million deaths yearly. Of the five species of Plasmodium, P. falciparum accounts for the most deadly form of the disease. P. falciparum survives under various physiological conditions during its life cycle. The parasite employs its molecular chaperones machinery particularly heat shock proteins (Hsps) to protect its protein constituents during physiological stress. Hsps are conserved molecules that constitute a major part of the cell’s molecular chaperone system. P. falciparum Hsps play an important cyto-protective role guaranteeing that the malarial parasite survives under the severe conditions that prevail in the host environment. PFF1010c is a type IV P. falciparum heat shock protein 40. PFF1010c is predicted to be expressed only at the gametocyte stage of the malarial parasite’s life cycle. The aim of the current study was to investigate the expression PFF1010c by parasites and the gametocyte stage as well as characterize the structure-function features of the protein. PFF1010c was successfully expressed in E. coli cells. Despite successful expression of the protein, its purification proved problematic. The attempt to purify PFF1010c was carried out under both native and denaturing conditions. Far Western blot analysis to investigate direct interaction between PFF1010c and PfHsp70-1 was conducted and no interaction was observed. Malarial parasites were harvested at different stages and total protein was isolated. The expression of PFF1010c was confirmed to occur at the gametocyte stage of the parasite’s development using Western blot analysis. This study confirmed that PFF1010c is only expressed at the gametocyte stage of the malarial parasite. Furthermore, PFF1010c was not expressed at the asexual stage. Possible interactors of PFF1010c were predicted by STRING, a bioinformatics based tool. The expression of PfHsp90, PfHop and PfHsp70-1 at the gametocyte stage was investigated and confirmed by Western blot analyses.

La découverte de l'Artémisinine, un 1,2,4-trioxacyclohexane, et le fait que la liaison endoperoxide est essentielle pour son activité antimalarique, a conduit les chimistes à la synthèse de nouvelles molécules contenant le motif endoperoxide pour obtenir de nouveaux leaders. Certains de ces composés peroxidiques sont les 1,2-dioxanes et les 1,2,4,5-tetraoxanes. À cet égard, la première partie de mon travail a été réalisée dans le laboratoire du professeur Giuseppe Campiani à l'université de Sienne et a inclus la synthèse d'analogues 1,2-dioxane du produit naturel Plakortine mais aussi le développement d'une stratégie de synthèse polyvalent du produit naturel 9,10-dihydroplakortine. Une des étapes clés dans notre approche synthétique a été la stéréosélectivité des réactions ainsi que la formation du squelette chiral 1,2-dioxane. En combinant l'époxidation dissymétrique de Sharpless à l'hydroperoxysilylation régiosélective d'alcène catalysée par le cobalt (II) de Mukaiyama-Isayama, la stéréochimie désirée a été obtenue. Dans la seconde partie de mon doctorat qui a pris place dans le laboratoire du professeur Paul O'Neill à l'université de Liverpool, la conception, la synthèse et l'évaluation du potentiel antimalarique de deux nouvelles séries de 1,2,4,5-tetraoxanes ont été réalisées. La première série de tetraoxanes, appelée les Mannoxanes, est une drogue hybride qui possède un noyau tetraoxane et une chaine latérale basique insérée grâce à une réaction de mannich. La seconde série a été préparée par une approche utilisant l'amination réductrice pour inclure la chaine latérale basique sur le noyau tetraoxane. Les deux séries ont montré d'excellentes activités antimalariques (de l'ordre du nanomolaire) contre plasmodium falciparum. / The discovery of artemisinin, a 1,2,4-trioxacyclohexane, and the fact that the endoperoxide bond is essential for its antimalarial activity has led chemists to synthesize new molecules containing the endoperoxide moiety in order to find new antimalarial hits. Some of these peroxidic compounds include the 1,2-dioxanes and the 1,2,4,5-tetraoxanes. In this regard, work on the first part of the PhD (Chapter 2) has been developed in the laboratories of Prof. Giuseppe Campiani at the University of Siena and includes the synthesis of 1,2-dioxane analogues of natural product Plakortin and the development of a versatile synthetic strategy to the natural compound 9,10-dihydroplakortin. One of the key issues in our synthetic approach has been the stereoselectivity of the reactions and the formation of the chiral 1,2-dioxane skeleton. By combining Sharpless asymmetric epoxidation to the Mukaiyama-Isayama Co(II)-catalyzed regioselective hydroperoxysilylation of an alkene, the desired stereochemistry has been obtained. In the second part of the PhD (Chapter 3), which has taken place in the laboratories of Prof. Paul O'Neill at the University of Liverpool, design, synthesis and assessment of the antimalarial potency of two new series of 1,2,4,5-tetraoxanes has been achieved. The first series of novel tetraoxanes are called Mannoxanes and are hybrid drugs that include a tetraoxane and a mannich basic phenol side-chain. The second new series has been synthesized by using a reductive amination approach to include the basic side chain in the tetraoxane molecule scaffold. Both of these series have shown excellent antimalarial activities against Plasmodium falciparum in the low nanomolar range.

En 2016, 216 millions de cas et 445000 décès liés au paludisme ont été reportés par l'Organisation Mondiale de la Santé (OMS), 90 % de ces cas ont eu lieu sur le continent africain, très majoritairement causés par Plasmodium falciparum. Chez les femmes enceintes le paludisme peut avoir de lourdes conséquences en termes de morbidité et de mortalité aussi bien pour la mère que pour l'enfant à venir. Outre l'utilisation de moustiquaires imprégnées, l'OMS recommande l'utilisation d'un traitement préventif intermittent par sulfadoxine-pyriméthamine (SP) pour les femmes enceintes des zones endémiques d'Afrique sub-saharienne. La résistance du parasite à la SP est un réel problème en l'absence d'alternative thérapeutique et le niveau de résistance est déjà très élevé dans certaines régions d'Afrique. Cette résistance est causée par différents polymorphismes nucléotidiques simples (SNPs) sur les gènes codant pour DHPS et DHFR. Ces mutations modifient la structure 3D de ces enzymes, diminuant leur liaison à la SP. Ce travail s'est attaché à faire un état des lieux récent de la prévalence des mutations des gènes pfdhfr et pfdhps à travers 7 sites d'Afrique Centrale. Un octuple mutant combinant trois mutations sur le gène pfdhfr et cinq mutations sur le gène pfdhps (CirnI + vagKgs) a été découvert à Yaoundé en 2015 ; nous l'avons retrouvé au Nigeria et au Cameroun mais pour la première fois à un haut niveau de prévalence à Maroua (52,2%). Sur plusieurs sites d'Afrique Centrale, nous décrivons l'augmentation de la prévalence de la mutation K540E, typique des parasites résistants de l'Afrique de l'Est et sur laquelle se base l'implémentation de la SP par l'OMS. D'autre part, à partir d'un modèle d'homologie de pfDHPS, nous avons utilisé des techniques de dynamique moléculaire pour mieux comprendre les modifications de la structure 3D liées à différents haplotypes d'intérêts retrouvés en Afrique Centrale. Cette partie de l'étude propose une autre approche pour évaluer et visualiser l'effet structurel des mutations, élément supplémentaire à la compréhension de leur impact sur la résistance à la SP. / Malaria was responsible for 445 000 death and 216 million new cases worldwide in 2016, 90% of these cases occurred in Africa. Pregnant women are particularly susceptible to malaria, resulting in medical consequences on both mother and child. In the endemic countries of sub Saharan Africa, in addition to the use of insecticidal nets, the World Health Organization (WHO) recommends a preventive treatment against Plasmodium falciparum malaria in pregnancy using Sulfadoxine Pyrimethamine (SP). Resistance of the parasite to SP is a significant problem in the absence of alternative treatment and the level of resistance is very high in some regions of Africa. This resistance is mediated by several single nucleotide polymorphisms (SNPs) in the genes coding for DHPS and DHFR, changing the 3D structure of the two target proteins and decreasing drug binding. This study offers an updated view of the epidemiology of these mutations throughout Central Africa. We identified for the first time the octuple mutant combining 3 mutations on pfdhfr gene and 5 mutations on pfdhps gene (CirnI + vagKgs), discovered in 2015 in Yaoundé, as the major haplotype in Maroua, northern Cameroon (52,2%). On several Central-African sites, we describe the increase of the prevalence of the typically East-African K540E mutation on which is based the implementation of SP by the WHO. Knowledge of the prevalence of resistance markers is crucial for the adaptation of SP recommendation in Central Africa. This study also explores the changes occurring in the 3D structure of the most common mutated pfDHPS haplotypes identified in our epidemiology study, using molecular dynamics on a homology model of the protein. It offers a new vision of the effect of the mutations on the structure, a further step to understanding the impact of mutations in resistance.

Malaria afflicts 300-500 million people in the world and the mortality ranges from 1-2 million, children in Africa being the most susceptible. With a vaccine not being available against malaria and the front line drugs such as chloroquine and antifolates registering widespread parasite resistance, the challenge of malaria treatment is a formidable task. While, research to discover new drugs has become essential, it has also become necessary to identify therapeutic strategies in the short-term. One approach is to examine whether known drugs used for other applications can be used to treat malaria. A second strategy is to look for natural compounds for antimalarial activity either singly or in combination. Combination therapy has assumed considerable importance in the context of artemisinin derivatives being the sole, tested, efficacious antimalarials left in the basket. A combination therapy with artemisinin derivative may prevent recrudescence due to monotherapy, extend the life of the drug and perhaps bring down the cost of therapy as well. A primary requirement to embark on such studies is to assess the status of drug resistance to the front line drugs in use. In India, chloroquine is still used as the front line drug for malaria therapy. Although, there have been indications and sporadic reports on the development of chloroquine resistance in the country, there has not been a detailed molecular or clinical evaluation for resistance. Keeping all these considerations in mind, the objectives of the present study are as follows: 1. Evaluation of chloroquine resistance inP.falciparum isolates from patients using Pfcrt-mutation as marker. 2. Evaluation of the anti-tubercular drugs, rifampicin and isonicotinic acid hydrazide (INH) for antimalarial activity. 3. Evaluation of curcumin from turmeric singly and in combination with α,β- arteether for antimalarial acitivity. Chapter I deals with the review of literature pertaining to scenario of available antimalarials, efforts to discover new antimalarials based on new drug targets, mechanisms of drug resistance and strategies for combination therapies. Chapter II deals with an evaluation of Pfcrt mutation in clinical samples of P.falciparum malaria in India. After several false starts to find molecular markers to identify chloroquine resistance, mutations in the Pfcrt gene of P.falciparum, K76T mutation in particular, has been shown to correlate very well with chloroquine resistance in culture. A study of 109 P.falciparum – infected blood samples from different parts of India has revealed that close to 95% of the isolates carry the K76T mutation. This was shown on the basis of susceptibility to ApoI restriction digestion of the PCR product covering this region (264 nt) and DNA sequencing of the PCR product. Interestingly, the resistant haplotype in this region of 72-76 amino acids was found to be mostly SVMNT, except for 4 samples with CVIET haplotype. SVMNT has all along been considered to be of South American origin, where as CVIET is of South East Asian/African origin. Subsequent studies by another group in the country has also shown that the Pfcrt - K76T mutation is seen at least in 85% of the cases and in addition to the dominant SVMNT haplotype, newer haplotypes are also seen. The present study has also included an analysis of N86Y mutation in the Pfmdr1 gene based on susceptibility to Afl III restriction enzyme digestion and DNA sequencing of the PCR product (603 nt). Pfmdr1 mutations have been extensively studied in literature for possible correlation to CQR. The net conclusion is that it does not contribute directly to CQR but may have an indirect correlation. It has been shown in Mali that there is very good correlation between Pfcrt - K76T mutation and Pfmdr1 - N86Y mutation in the P.falciparum isolates. However, in the present study with Indian isolates only around 30% of the samples were found to carry the Pfmdr1 - N86Y mutation. While, further studies on the clinical relevance of the extensive Pfcrt mutation seen in the Indian isolates are needed, it is clear that the genetic change towards chloroquine resistance has already taken place in the Indian context. Chapter III is devoted to a study of the antimalarial effects of the anti-tubercular drugs, rifampicin and INH. This is on the basis that rifampicin is an inhibitor of prokaryotic and mitochondrial/chloroplast RNA polymerase. P.falciparum harbors the apicoplast, a remnant of chloroplast with a 35kb DNA. It is known that the β, β’- subunits of the apicoplast RNA polymerase are coded by the apicoplast DNA. There is a report that rifampicin is a slow acting antimalarial in cases of P.vivax -nfection. INH is known to act by inhibiting the enoyl-ACP reductase and β - hydroxy ACP synthase in M.tuberculosis. While, M.tuberculosis is known to manifest Fab I and Fab II pathways of fatty acid biosynthesis, it has recently been shown that P.falciparum manifests the FabII (discrete enzymes) pathway. Thus, it was considered possible that INH may also inhibit the fatty acid biosynthetic pathway of P.falciparum leading to inhibition of phospohlipid and membrane biosynthesis. Studies were, therefore, carried out with rifampicin, INH and the combination on the survival of P.falciparum in culture and P.berghei in mice. With P.falciparum, growth was followed by measuring3[H]-Hypoxanthine incorporation and slide detection of parasites using Giemsa stain. The results indicate that while, rifampicin inhibits P.falciparum growth with an IC50 around 25nM, and INH fails to show any effect even at 200µM concentration. The combination of rifampicin (25nM) and INH (100µM) shows enhanced killing effect. In view of these results, studies were undertaken in mice infected with P.berghei. After 72 hr infection, the mice were orally fed with rifampicin (500 µg/40 g body weight) or INH (1 mg/40 g body weight) or a combination of the two orally for 5 days, starting on day 3. Apart from parasite clearance in blood, protection against mortality is a good index, since all the infected mice die in about 7-8 days. The results indicate that rifampicin leads to around 50% protection and INH treatment gives around 10% protection. However, the combination gives around 83% protection with complete clearance of the parasite in blood. Short- term treatment of infected mice with drugs and an assay of rpoB/C transcription in the parasite using appropriate PCR primers reveal a striking inhibition in combination treatment. Again, when such parasites were put into short-term culture and32P- incorporation into phospholipids was measured, there was striking inhibition with combination treatment. Thus, the results indicate that a combination of rifampicin and INH has potent antimalarial activity in P.berghei-infected mice. The results are dramatic in this case when compared to the results obtained with P.falciparum culture. It is not clear whether the differences are due to differences in action in vitro vs in vivo or due to differences in susceptibility between P.falciparum and P. berghei to the treatment provided. Chapter IV deals with the antimalarial activity of curcumin (diferuloyl methane) from turmeric singly or in combination with artemesinin or its derivative. Curcumin is reported to have a wide variety of biochemical effects and its anti-cancer activity is under serious investigation. There is an earlier report that curcumin shows antimalarial activity against chloroquine-sensitive P.falciparum. In the present study, curcumin was tested against a chloroquine-resistant culture of P.facliparum and it inhibits growth with an IC50 of 5-8 µM. When P.berghei-infected mice were orally fed with curcumin for 5 days, there was delay in the development of parasitemia, with about 30% of the animals protected against mortality by day 28. For reasons mentioned earlier curcumin was tested in combination with artemisinin/derivative in P.falciparum culture and P.berghei in mice. The results indicate that artemisinin and curcumin have an additive inhibitory effect on P.falciparum growth, based on a detailed analysis of the isobolograms. In terms of the mechanism of action, curcumin treatment leads to accumulation of45Ca in the parasite cytoplasm. It also has a striking inhibitory effect on32P-incorporation into parasite proteins and phospholipids, suggesting an interference with phosphorylation mechanisms. None of these effects are seen under artemisinin treatment, which has been reported to specifically inhibit PfATP6 (Ca ATPase) in P.falciparum. In view of the possible different modes of action of artemisinin and curcumin, the combination was tested in P.berghei-infected mice. The infected mice received a single injection of α,β-arteether and 3 oral doses of curcumin (5mg/30g body weight). Curcumin treatment was found to dramatically delay the onset of parasitemia seen in animals treated with α,β-arteether alone due to recrudescence. In particular, a combination with a single injection of α,β-arteether (750µg or 1.5mg/30g body weight) followed by 3 oral doses of curcumin leads to complete prevention of recrudescence and 100% protection against mortality. Several combinations with artemisinin derivative are under investigation and they all suffer from toxic side effects, pharmacokinetic mismatch, known resistance to the combining partner and high cost. It is felt that this artemisinin derivative curcumin combination could prove superior in view of the fact that no resistance is known to curcumin and is safe even at very high doses used in the human. Both the drugs are eliminated fast and curcumin is a cheap chemical and available in plenty from natural source (turmeric). In view of these positive attributes, a clinical trial with this combination is recommended. 121

Thesis (MSc)--Stellenbosch University, 2015. / ENGLISH ABSTRACT: Having caused the deaths of more than 10 million individuals since 2000 with most of them occurring in Africa, malaria remains a serious disease that requires undivided attention. To this end a detailed kinetic model of Plasmodium falciparum glycolysis was constructed, validated and used to determine potential drug targets for the development of novel, effective antimalarial therapies. The kinetic model described the behaviour of the glycolytic enzymes with a set of ordinary differential equations that was solved to obtain the steady state fluxes and concentrations of internal metabolites. The model included a glycerol branch represented in a single fitted equation. This present study set out to detect, characterise, and incorporate into the model the enzymes that constitute the glycerol branch of P. falciparum glycolysis. The kinetic parameters of glycerol 3-phosphate dehydrogenase (G3PDH), the first enzyme in the branch and catalyst of the dihydroxyacetone phosphosate (DHAP) reducing reaction, was determined and added to the detailed kinetic model. The model was subsequently validated by comparing its prediction of steady state fluxes with experimentally measured fluxes. Once it was evident that the predictions of the unfitted model agreed with experimentally measured fluxes, metabolic control analysis was performed on this branched system to ascertain the distribution of control over the steady state flux through the glycerol branch. The control G3PDH exercised over its own flux was less than expected due to the enzyme’s sensitivity to changes in NADH and thus the redox balance of the cell. Attempts were made to detect the enzymes responsible for the conversion of glycerol 3-phosphate (G3P) to glycerol. Very low levels of glycerol kinase activity was observed. Although G3P-dependent release of inorganic phosphate was detected results were inconclusive as to whether a non-specific phosphatase also mediated the conversion. Overall, the expansion of the model to include G3PDH did not affect the steady state metabolite concentrations and flux adversely. / AFRIKAANSE OPSOMMING: Vanaf die jaar 2000 het malaria die dood van meer as 10 miljoen mense veroorsaak. Die meeste sterftes het in Afrika voorgekom —’n aanduiding van hoe ernstige siekte dit is en een wat onverdeelde aandag moet geniet. Om hierdie rede is ’n gedetaileerde kinetiese model van glikoliese in Plasmodium falciparum gebou, gevalideer en gebruik om potensiële dwelm teikens te identifiseer vir die ontwikkeling van nuwe, meer effektiewe anti-malaria terapieë. Die kinetiese model beskryf die gedrag van die glikolitiese ensieme in terme van gewone differensiële vergelykings wat opgelos is om die bestendige toestand fluksies en interne metaboliet konsentrasies te bepaal. Die model sluit ’n gliserol-tak in wat deur ’n enkele aangepaste vergelyking verteenwoordig word. Hierdie studie het voorgeneem om die ensieme van die gliserol-tak van P. falciparum glikoliese te identifiseer, karakteriseer en in die model te inkorporeer. Ons het die kinetiese parameters van die eerste ensiem in die gliserol-tak, gliserol 3-fosfaat dehidrogenase (G3PDH), die katalis van die dihidroksiasetoon fosfaat(DHAP) reduserende reaksie, bepaal. Die kinetiese parameters is by die gedetaileerde model gevoeg. Validering het plaasgevind deur die model se voorspellings met eksperimenteel bepaalde waardes te vergelyk. Toe dit duidelik geword het dat die voorspellings van die model met die eksperimenteel bepaalde fluks ooreenstem, is metaboliese kontrole analiese op die vertakte sisteem uitgevoer. Dit is gedoen om vas te stel hoe die bestendige toestand fluks deur die gliserol-tak beheer word. G3PDH het nie volle beheer oor sy eie fluks nie, in teenstelling met ons vergewagtinge. Daar is gepoog om vas te stel watter ensieme verantwoordelik is vir die produksie van gliserol vanuit gliserol 3-fosfaat (G3P). ’n Lae gliserolkinase aktiwiteit is waargeneem. Alhoewel G3P afhanklike vrystelling van anorganise fosfaat waargeneem is, is dit nie duidelik vanuit die resultate of die proses deur ’n nie-spesifieke fosfatase uitgevoer word nie. Die uitbreiding van die model om ’n G3PDH vergelyking in te sluit het nie die bestendige toestand metaboliet konsentrasies en fluks negatief geaffekteer nie.

Three protein targets are used in malaria rapid diagnostic tests (RDTs). These are Plasmodium falciparum histidine rich protein 2, Plasmodium lactate dehydrogenase and aldolase. A thrust of research in RDTs is to improve on their specificity and sensitivity. In this study the current diagnostic target, P. falciparum lactate dehydrogenase (PƒLDH) was compared to a new target glyceraldehyde-3-phosphate dehydrogenase (PƒGAPDH) that was identified based on transcriptional data. These proteins are conserved amongst all Plasmodium species, with minor amino acid sequence variations which were evaluated as possible species-specific peptide epitopes for PƒLDH: LISDAELEAIFDRC and PƒGAPDH: CADGFLLIGEKKVSVFA; CAEKDPSQIPWGKCQV, where common peptides were identified as pan-malarial epitopes for pLDH: APGKSDKEWNRDDLC and pGAPDH: CKDDTPIYVMGINH. The chosen peptides were located on the surface of their predicted 3D crystal structure models. Antibodies were raised against these peptides in chickens (IgY) and affinity purified. PƒLDH and PƒGAPDH were recombinantly expressed in E. coli BL21(DE3) cells and their coding inserts confirmed by sequencing. The recombinant proteins were detected in Western blots with specific anti-His₆ tag antibodies at approximately 35 kD (PƒLDH ~ 36 kD and PƒGAPDH ~ 39 kD) which compared with their expected values. Both recombinant proteins were found to form tetramers in solution and were used to raise IgY antibodies for comparison of Pheroids™ and Freund’s adjuvants. Pheroids™, like Freund’s appeared to exhibit a depot effect, however Freund’s adjuvant gave higher affinity purified IgY yields. The anti-recombinant and anti-peptide IgY specifically detected their respective recombinant and native antigens and did not cross-react with other human blood proteins. Immunoprecipitation detected higher levels of PƒGAPDH to PƒLDH in P. falciparum culture lysates. A double antibody sandwich ELISA detected 17.3 ng/ml PƒLDH and 138.5 ng/ml PƒGAPDH at 1% parasitemia in in vitro cultures, however this needs to be further evaluated. These findings suggest PƒGAPDH to be at least as good a protein target as PƒLDH for malaria diagnosis and further trials using it as a target in an RDT format should be considered. / Thesis (M.Sc.)-University of KwaZulu-Natal, Pietermaritzburg, 2012.

Plasmodium falciparum, the most virulent malarial parasite, is capable of invading all known human blood types. Erythrocyte invasion depends on specific parasite ligand and erythrocyte receptor interactions. These interactions are mediated by Region II of the P. falciparum erythrocyte binding ligands. Although invasion does not seem dependent upon a singular ligand, their individual contributions to the invasion process are yet to be explained. In this study, Region II of P. falciparum binding ligands BAEBL and JESEBL were transiently expressed as hexahistidyl recombinant proteins in COS-1 cells. Purification by column chromatography yielded 0.52 mg of BAEBL and 0.433 mg of JESEBL. The production and purification of these recombinant hexahistidyl proteins can allow for future binding affinity and kinetic analysis that may eventually define the contributive roles of each ligand during erythrocyte invasion.

Plasmodium falciparum (P. falciparum) infection modulates the response of innate immune cells. The aim of this work was to study the impact of P. falciparum infection and P. falciparum-derived molecules on the response of dendritic cells (DC) and monocytes. In paper I we investigated the effects of natural hemozoin (nHZ), a P. falciparum-derived molecule, on the phenotype and functionality of DC. We found that exposure to nHZ impaired the capacity of DC to mature. Paper II is a follow-up on paper I, where the underlying transcriptional events preceding the nHZ-induced impairment of DC maturation were investigated. More specifically, we examined the involvement of certain transcription factors, subunits of chromatin remodeling complexes and histone modifications in the regulation of DC maturation. Our findings suggest that nHZ-exposure of DC does not lead to recruitment or enrichment of molecules needed for transcriptional activation. In paper III we investigated P. falciparum effects in vivo in sympatric ethnic groups with differential susceptibility towards P. falciparum infection living in Burkina Faso. The aim of this study was to establish the transcriptional networks underlying the relatively better protection against P. falciparum infection observed in the Fulani ethnic group compared to other sympatric ethnic groups. Our findings reveal differential gene expression in monocytes of infected Fulani compared to uninfected Fulani and the difference concerned multiple classes of genes including signal transduction, immunological responses and chromatin remodelers. The results provide new aspects on molecules and regulatory mechanisms that are involved in the relatively more protective response against P. falciparum infection. Taken together, the work presented in this thesis leads to a deeper understanding of the P. falciparum-induced modulation of responses of innate immune cells and the underlying mechanisms possibly regulating those responses. / <p>At the time of the doctoral defense, the following papers were unpublished and had a status as follows: Paper 2: Manuscript. Paper 3: Manuscript.</p>

Malaria ist eine schwerwiegende Krankheit, die jährlich über eine Million Menschen tötet. Die zunehmende Resistenzbildung gegenüber den verwendeten Medikamenten macht die Entwicklung neuer Antimalariamittel dringend notwendig. Daher sind die Vitamin B6 Synthese und der Shikimatweg von besonderem Interesse, da diese beiden Synthesewege nur im Parasiten und nicht im Menschen vorkommen. Unter der Voraussetzung, dass diese essentiell für den Parasiten sind, böten sie ideale Ansatzpunkte zur Entwicklung neuer Antimalariamittel. Voraus gegangene Studien haben gezeigt, dass Plasmodium falciparum in der Lage ist, PLP de novo mittels eines bifunktionalen Enzymkomplex, bestehend aus den Proteinen Pdx1 und Pdx2, zu synthetisieren. Pdx1 stellt dabei die eigentliche Synthase dar, während Pdx2 als Glutaminase-Partner das benötigte Ammoniumion für den heterocyclen Ring bereitstellt. Zusätzlich dazu verfügt der Parasit auch über einen salvage pathway um PLP zu „recyclen“, in dem der Pyridoxalkinase PdxK eine Schlüsselfunktion zufällt. Knockout Studien der pdx1 im Mausmalariasystem P. berghei haben gezeigt, dass PbPdx1 für eine optimale Entwicklung der Blutstadien benötigt wird, nicht jedoch für deren Überleben. Im Rahmen dieser Arbeit habe ich die Effekte eines pbpdxK(-) Knockouts in demselben System untersucht. Es konnte eine monoklonale Knockoutlinie generiert werden, was zeigte, dass PbPdxK nicht essentiell für das Überleben des Parasiten in den Blutstadien ist. Die Entwicklung während des Blutstadiums war von dem pbpdxK(-) Knockout nicht betroffen. Allerdings zeigte sich im Moskitostadium eine drastische Reduktion der Sporozoitenzahl sowohl in den Mitteldärmen als auch in den Speicheldrüsen. Dieses Ergebnis legt nahe, dass PbPdxK essentiell für das Überleben der Sporozoiten ist. Daneben wurde versucht, die Gene pfpdx1, pfpdx2 sowie pfpdxK in P. falciparum 3D7 durch Verwendung der single cross over Strategie auszuschalten. Es konnte jedoch für keines der genannten Konstrukte eine Integration in die jeweiligen Genloci anhand von PCR-Analysen nachgewiesen werden. Ebenso scheiterte der Versuch, durch Rekombination eines komplementären Genabschnitts die Funktion des Gens zu rekonstituieren. Daher bleibt es unklar, ob pfpdx1, pfpdx2 und pfpdxK durch Knockout Strategien auszuschalten sind oder nur für Genmanipulationen nicht zugänglich sind. Die Kultivierung von P. falciparum 3D7 Parasiten in Vitamin B6 depletiertem Medium hatte keinen Effekt auf deren Wachstum. Eine anschließende Analyse der Proteinextrakte zeigte eine erhöhte Expression der PfPdxK, während sich das Expressionslevel der PfPdx1 nicht veränderte. Es scheint, dass der Parasit in der Lage ist Vitamin B6 Mangel durch vermehrte Nutzung des salvage pathways vollständig zu kompensieren. Frühere Arbeiten zeigten, dass der C-Terminus der Pdx1 in die Aktivität des PLP Synthasekomplexes involviert ist. Aus diesem Grund wurden verschiedene C-terminale Deletionsmutanten der PfPdx1 konstruiert und dabei bis zu 30 Aminosäuren entfernt. Diese Analysen ergaben, dass der C-Terminus vier verschiedene Funktionen besitzt: das Assembly der Pdx1 Untereinheiten zum Dodekamer, die Bindung des Pentosesubstrats Ribose 5-Phosphat, die Bildung des Intermediats I320 und schließlich die PLP Synthese. Diese unterschiedlichen Funktionen wurden durch verschiedene Deletionsvarianten identifiziert. Darüber hinaus waren alle Deletionsvarianten in der Lage, die Glutaminase Pdx2 zu aktivieren, was zeigt, dass das Dodekamer nicht Vorraussetzung für die Glutaminaseaktivität ist. Aufgrund der geringen PLP Syntheseaktivität in vitro wurde vermutet, dass der PfPdx1/PfPdx2 Komplex durch einen zusätzlichen Faktor aktiviert wird. Daher wurde versucht, mittels Yeast 2-Hybrid, basierend auf einer PCR-amplifizierten P. falciparum 3D7 cDNA-Bibliothek als bait und PfPdx1 als prey, einen Interaktionspartner zu identifizieren. Mehrere Klone wurden gewonnen, die alle einen Bereich des Mal13P1.540, einem putativen Hsp70 Proteins, enthielten. Jedoch scheiterten alle Versuche, die Protein-Protein-Interaktion mit rekombinant exprimierten Protein zu bestätigen. Ebenso war es nicht möglich, das vollständige Mal13P1.540 rekombinant zu exprimieren sowie dessen Lokalisation in vivo zu bestimmen. Daher bleibt die Interaktion von PfPdx1 und Mal13P1.540 ungeklärt. Neben der Vitamin B6 Biosynthese konnten auch einige Gene des Shikimatweges in Plasmodium identifiziert werden. In P. berghei konnten der C-terminale Teil der 3-Dehydroquinatsynthase (2) sowie die Shikimatkinase (5) und die 5-Enoylpyruvylshikimat 3-Phosphatsynthase (6) in einem open reading frame (ORF) identifiziert werden, der dieselbe genetische Organisation aufweisen wie der Arom-Komplex der Hefen. Mit Hilfe eines Komplementationsassay wurde die Funktionalität dieses ORFs überprüft. Dazu wurden S. cerevisiae BY4741Δaro1, ein Hefestamm ohne funktionalen Arom-Komplex, mit dem Pb2_6_5_ABC Fragment transformiert. Die so transformierten Hefen waren nicht in der Lage, auf Mangelplatten ohne aromatische Aminosäuren zu wachsen, was zeigte, dass das Pb2_6_5_ABC Konstrukt den BY4741Δaro1 Phänotyp nicht komplementieren konnte. Der Versuch, mit Hilfe des Baculovirussytems rekombiant exprimiertes Protein zu erhalten, verlief erfolglos. Ebenso war es nicht möglich, Teile des Proteins für Immunisierungen zu exprimieren. Daher bleibt die Funktionalität des Pb2_6_5_ABC Konstruktes ungeklärt. / Malaria is a serious burden of mankind causing over one million deaths a year. In view of the raising number of resistances to common drugs there is an urgent need for the development of new antimalarial drugs. In this respect, the vitamin B6 biosynthesis and the shikimate pathway are of particular interest, since these synthesis pathways are only present in the malarial parasites and not in their human host. Given their essentiality for the parasite, they would represent ideal targets for antimalarial drug development. Previous studies revealed that Plasmodium falciparum is able to produce PLP de novo through a bifunctional enzyme complex composed of the proteins Pdx1 and Pdx2, of which Pdx1 is the actual synthase and Pdx2 the glutaminase partner providing the nitrogen for the ring system. In addition, the parasites possess a salvage pathway for PLP, of which pyridoxal kinase, PdxK, is a key player. Knockout studies of the pdx1 in the rodent malaria system P. berghei showed, that pbpdx1 is required for the optimal development of parasite blood stages but is not essential for parasite survival. Here, I investigated the effect of a pbpdxK(-) knockout in the same system. A monoclonal knockout strain was obtained, indicating that PbPdxK is not essential for the survival of the parasite. Blood stages were not affected by the knockout. However, in the mosquito stages pbpdxK(-) showed a tremendous reduction of sporozoites numbers in the midgut and in the salivary glands, indicating that PbPdxK is essential for the survival of sporozoites. It was then also tried to knockout pfpdx1, pfpdx2 and pfpdxK in the P. falciparum 3D7 strain by using the single cross over strategy. However, no integration of the constructs in the corresponding gene locus could be detected by a PCR approach. Also an approach to complement the loss of endogenous gene function by generating a functional gene copy upon recombination failed. Thus, it remains unclear if pfpdx1, pfpdx2 and pfpdxK can be knocked out or are inaccessible for gene targeting in P. falciparum. Cultivation of P. falciparum 3D7 parasites in medium deficient of vitamin B6 showed no effect on the growth rate of the parasites. Analysis of protein extracts of these parasites revealed an upregulation of PfPdxK expression, whereas the level of PfPdx1 remained stable. Thus it seems that the parasite is fully able to compensate vitamin B6 malnutrition by the increased usage of the salvage pathway. Previous studies on the activity of the PLP synthase complex indicated that the C-terminal end of Pdx1 is involved in PLP formation. Therefore several C-terminal deletion mutants of PfPdx1 were constructed, removing up to 30 amino acids. These analyses revealed that the C-terminus has four distinct functionalities: assembly of the Pdx1 monomers, binding of the pentose substrate (ribose 5-phosphate), formation of the reaction intermediate I320, and finally PLP synthesis. Deletions of distinct C-terminal regions distinguish between these individual functions. All variants were able to activate the glutaminase PfPdx2, indicating that the dodecameric structure is not a prerequisite for Pdx2 activation. Due to the low PLP synthase activity in vitro it was assumed that the PfPdx1/PfPdx2 complex maybe activated by an additional protein. Hence a yeast 2-hybrid assay was performed, using PfPdx1 as prey and a PCR-amplified cDNA-library of P. falciparum 3D7 as bait. Several clones were detected on high stringency plates, containing all a region of Mal13P1.540, a putative Hsp70 protein. Trials to confirm protein-protein interaction with recombinantly produced proteins failed as well as protein expression of full length Mal13P1.540. It was also not possible to determine the localisation of Mal13P1.540 in vivo. Thus, an interaction of PfPdx1 with Mal13P1.540 could so far not be verified. Besides the vitamin B6 biosynthesis, some genes of the shikimate pathway were identified in Plasmodium. In P. berghei, the C-terminal part of the dehydroquinatesynthase (2) as well as the shikimate kinase (5) and 5-enoylpyruvylshikimate 3-phosphatesynthase (6) were found in a single open reading frame having the same organisation as the arom-complex of yeast. To proof the functionality of these genes a complementation assay with S. cerevisiae BY4741Δaro1 with the Pb2_6_5_ABC construct, comprising the above mentioned genes, was performed. However, transformded yeast strains were not able to grow on minimal media without aromatic amino acids, indicating that they were not able to produce chorismate. Recombinant expression of this constructs in the baculovirussystem did not yield any detectable protein. Expression of parts of this protein for immunisation was also not successful. Hence, the functionality of this protein remains to be established.

La découverte de nouveaux agents antipaludiques est primordiale. A travers le monde, les chercheurs se sont focalisés sur plusieurs stratégies. Les plus développées sont : soit les tests de molécules issues de bibliothèques chimiques dans une recherche phénotypique (comme le test direct d’agents sur des cultures de parasites in vitro), soit la recherche de nouvelles molécules agissant sur l’activité d’une cible ou d’une voie spécifique et essentielle. Cette thèse est centrée sur le second type d’approche. Nous nous sommes intéressés aux transporteurs membranaires de P. falciparum. Pour cela, nous exprimons les protéines d’intérêt dans la levure et nous les purifions. Nous optimisons les tests fonctionnels, dans le but de : a) déterminer l’effet des molécules sur les cibles spécifiques ; b) tester leur effet sur les cultures d’érythrocytes infectés par P. falciparum in vitro ; c) vérifier leur toxicité sur des cellules de mammifères ; et d) réaliser le test des molécules les plus efficaces in vivo dans un modèle de paludisme murin. Notre travail actuel est focalisé sur l’ATPase6 de P. falciparum (PfATP6) et l’adénylate translocase (PfAdT), deux protéines membranaires essentielles localisées respectivement sur le réticulum endoplasmique et la membrane mitochondriale. Nous exprimons de manière hétérologue PfATP6 dans les membranes de levure, nous purifions la protéine et mesurons une activité ATPase spécifique. Nous avons ainsi pu tester une bibliothèque chimique importante et identifier des inhibiteurs spécifiques. Ces derniers ont ensuite été testés pour évaluer leur effet sur les stades érythrocytaires du parasite in vitro et leur cytotoxicité sur des cellules de mammifères. Pour le transporteur PfAdT, nous procédons comme pour PfATP6, mais nous avons choisi un autre type de test fonctionnel dans lequel la protéine est directement exprimée sur la membrane plasmique d’E. coli. Cela devrait permettre de mesurer le transport d’ATP radiomarqué, et l’identification d’inhibiteurs spécifiques dont les effets pourront être évalués sur des cultures de parasites in vitro et dans des essais de cytotoxicité. / New drug discovery for malaria treatment urges, now more than ever. There is no optimal solution to the search for new antimalarials. Worldwide, researchers have focused their energies on several strategies. The most commonly employed are: either by screening molecules issued from chemical libraries in a phenotypic way (i.e., direct testing of drugs on in vitro parasite cultures), or by searching for new molecules acting upon the activity of a specific essential target or pathway. This PhD thesis centers on the second type of approach. We are interested in targeting membrane transporters of P. falciparum. For this, we plan to express proteins of interest in yeast and proceed to their isolation. With optimized functional tests, we aim to: a) Determine the effect of molecules upon specific targets; b) Test their effect on P. falciparum in vitro erythrocytes cultures; c) As well as verify their toxicity on mammalian cells; and d) Perform in vivo testing of the best molecules on a rodent model for malaria. Our actual work is focused on the P. falciparum Ca2+ - ATPase 6 (PfATP6) and adenylate translocase (PfAdT), two essential membrane proteins localized on the endoplasmic-reticulum and the mitochondrial membrane, respectively. We were able to express heterologously PfATP6 in yeast membranes, purify the protein and measure a specific ATPase activity. With this, we have tested a large chemical library and identified specific inhibitors. These were then tested for their effect on in vitro blood stages of P. falciparum and for their cytotoxicity on mammalian cells. For the ATP/ADP carrier PfAdT, we proceeded as previously done with PfATP6 but we have also chosen another type of functional test where we express directly this protein in the plasma membrane of E. coli. This will enable in the future the measurement of radiolabelled ATP uptake, and the identification of specific inhibitors that could then be tested for their effect on P. falciparum in vitro cultures and for their cytotoxicity.